Not Yet Recruiting PHASE2 INTERVENTIONAL 5-arm
NCT07448922
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignancies
Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Conditions
Advanced Gynecological Malignancies
Interventions
Bevacizumab Carboplatin (AUC 5) SKB518 for injection
Updated 1 time since 2026 Last updated: Feb 27, 2026 Started: Mar 25, 2026 Primary completion: Dec 31, 2027 Completion: Sep 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Advanced Gynecological Malignancies and is currently actively recruiting participants. Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Data source: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .